Tasigna (nilotinib) is a chemotherapy drug originally approved to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Tasigna can have serious and life-threatening side effects, including the development of atherosclerosis. When the drug was approved by the U.S. Food and Drug Administration (FDA) in 2007, it carried … [Read more...]
FDA Will ‘Take Another Look’ at Controversial Parkinson’s Drug
When, two years ago, the FDA reviewed the Parkinson’s drug, Nuplazid, lead medical reviewer Dr. Paul Andreason issued grave warnings about the potential risks. During the review process, he observed that those taking the actual medication were suffering extreme side-effects (including death) twice as much as those taking placebos. In addition, he … [Read more...]
Nuplazid Deaths
Nuplazid (pimavanserin) is a new-generation Parkinson’s disease drug, introduced in April 2016. The U.S. Food and Drug Administration (FDA) has already received at least 5,735 adverse event reports including 712 deaths linked to Nuplazid in the short time that it has been on the market. The drug is made by Acadia Pharmaceuticals and is an atypical … [Read more...]
Antidepressant Withdrawal: Are the Benefits Worth the Risk of Dependence?
After a New York Times story written last week detailed the ravages of anti-depressant withdrawal, US Recall News spoke to a Manhattan psychopharmacologist and several New York City patients who are taking antidepressants--or have weaned themselves off of them--to find out whether the drugs’ benefits are worth the price of withdrawal. We also … [Read more...]
Limbrel Recall
At the request of the U.S. Food and Drug Administration (FDA), Primus Pharmaceuticals, Inc. issued a voluntary recall of Limbrel (flavocoxid), in January 2018. Limbrel use has been associated with liver injury and hypersensitivity pneumonitis, a condition in which the alveoli of the lungs become inflamed. Limbrel is a dietary supplement, … [Read more...]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 40
- Next Page »
Recent Comments